Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/908 Devices Inc./ 8-K

Current Report · Items 2.02, 9.01 · 8-K

908 Devices Inc.

MASSNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 20, 2026, 908 Devices Inc. (“908 Devices”) announced its preliminary financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.…

Filed Jan 20, 2026Accepted Jan 20, 2026, 7:15 AM ESTCIK 1555279Accession 0001104659-26-004798
View company →Permanent SEC source ↗
Share

Company context

908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit www.908devices.com.

Current securities

MASSNASDAQ · EQUITY · Current

Recent company filings

  1. 4 filingSep 25, 2026
  2. 144 filingSep 15, 2026
  3. 4 filingAug 24, 2026
  4. 144 filingAug 17, 2026
  5. SCHEDULE 13G/A filingAug 14, 2026

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition. On January 20, 2026, 908 Devices Inc. (“908 Devices”) announced its preliminary financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. The information contained in Item 2.02 of this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) mass-20260120xex99d1.htm

EX-99.1 2 mass-20260120xex99d1.htm EX-99.1 Exhibit 99.1 908 Devices Announces Strong Preliminary Financial Results for Fourth Quarter and Full Year 2025 Preliminary full year 2025 revenue of approximately $56 million, representing ~17% growth year-over-year Achieved positive Adjusted EBITDA goal in the fourth quarter BURLINGTON, Mass. - January 20, 2026 - 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced preliminary unaudited financial results for the quarter and full year ended December 31, 2025. Preliminary unaudited revenue for the fourth quarter of 2025 is approximately $17.2 million, compared to $14.3 million in the fourth quarter of 2024, reflecting reported growth of approximately 20%. Fourth quarter strength was driven by continued overperformance within the U.S. state and local channel, ramping adoption of VipIR internationally, and sales to federal and defense customers. Preliminary unaudited revenue for the year ended December 31, 2025 is expected to be approximately $56.0 million, compared to audited revenue of $47.7 …

Open exhibit ↗